title: Lipidomics in drug development.
abstract: Numerous human pathologies, including common conditions such as obesity, diabetes, cardiovascular disease, cancer, inflammatory disease and neurodegeneration, involve changes in lipid metabolism. Likewise, a growing number of drugs are being developed that directly or indirectly affect lipid metabolic pathways. Instead of classical and cumbrous radiochemical analyses, lipid profiling by mass spectrometry (MS)-based lipidomics holds great potential as companion diagnostic in several steps along the drug development process. In this review we describe some typical lipidomics set-ups and illustrate how these technologies can be implemented in target discovery, compound screening, in vitro and in vivo preclinical testing, toxicity testing of drugs, and prediction and monitoring of response.
authors.affiliation: KU Leuven - University of Leuven, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, B-3000 Leuven, Belgium.
authors.forename: Jonas
authors.initials: J
authors.lastname: Dehairs
authors.affiliation: KU Leuven - University of Leuven, Department of Cellular and Molecular Medicine, Laboratory of Protein Phosphorylation and Proteomics, B-3000 Leuven, Belgium.
authors.forename: Rita
authors.initials: R
authors.lastname: Derua
authors.affiliation: KU Leuven - University of Leuven, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, B-3000 Leuven, Belgium.
authors.forename: Natalia
authors.initials: N
authors.lastname: Rueda-Rincon
authors.affiliation: KU Leuven - University of Leuven, Department of Oncology, Laboratory of Lipid Metabolism and Cancer, B-3000 Leuven, Belgium. Electronic address: johan.swinnen@med.kuleuven.be.
authors.forename: Johannes V
authors.initials: JV
authors.lastname: Swinnen
mesh_terms: D055808:Drug Discovery; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D050356:Lipid Metabolism; D055432:Metabolomics; D058990:Molecular Targeted Therapy